REGN•benzinga•
Regeneron Pipeline Aims To Address $220 Billion Therapeutic Opportunities By 2030
Summary
Regeneron promotes EYLEA, Libtayo, and Dupixent at JPMorgan event while touting a pipeline that targets major disease areas.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 14, 2025 by benzinga